Free tool
FAERS Monitor: Arazlo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211882 or its brand name (Arazlo, Tazarotene). Reports on generic versions are filed under their own applications.
Reports
350
Serious
137
39% of reports
Hospitalization
56
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective55
- off label use34
- headache21
- diarrhoea17
- nausea16
- product use in unapproved indication16
- dry skin15
- psoriasis15
- application site discolouration14
- pain14
- skin exfoliation14
- treatment failure14
- erythema12
- pruritus12
- acne11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 13 |
| 2017 | 3 |
| 2018 | 11 |
| 2019 | 22 |
| 2020 | 13 |
| 2021 | 20 |
| 2022 | 40 |
| 2023 | 72 |
| 2024 | 48 |
| 2025 | 35 |
| 2026 | 46 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,809 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site discolourationSignal | 14 | 207.8 | 124.3 | 2,669 |
| treatment failureSignal | 14 | 10.2 | 6.1 | 107 |
| skin exfoliationSignal | 14 | 10.0 | 6.0 | 105 |
| acneSignal | 11 | 8.7 | 4.9 | 68 |
| psoriasisSignal | 15 | 6.9 | 4.2 | 70 |
| dry skinSignal | 15 | 6.8 | 4.1 | 68 |
| product use in unapproved indicationSignal | 16 | 3.9 | 2.4 | 32 |
| erythemaSignal | 12 | 3.5 | 2.0 | 19 |
| drug ineffectiveSignal | 55 | 2.5 | 2.0 | 52 |
| off label useSignal | 34 | 2.3 | 1.7 | 26 |
| headacheSignal | 21 | 2.0 | 1.3 | 10 |
| pruritus | 12 | 1.9 | 1.1 | 4 |
| diarrhoea | 17 | 1.6 | 1.0 | 3 |
| pain | 14 | 1.4 | 0.8 | 1 |
| nausea | 16 | 1.2 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.